Drug rimonabant

Since the limited launch of the drug in the EU in the third quarter, rimonabant diet pill sales have been roughly $15 million. But sales should increase much faster as Sanofi gets the word out about rimonabant via marketing and other measures.Earlier in the week, Sanofi released results from a ...

SERENADE Trial SERENADE (Study Evaluating Rimonabant Efficacy in Drug Naive Diabetic Patients) was a six-month phase IIIb, multinational, multicenter, randomized, double-blind and placebo-controlled trial carried out at ...

The main task of Acomplia Rimonabant diet pills is that it blocks the CB-1 receptors, which are found in brain in addition to some of the body’s peripheral tissues such as fat cells. Apart from its benefits in weight loss the diet drug is also effective for smoking cessation. There ...

Acomplia Rimonabant Mexico The world's third largest drug maker, French drug maker Sanofi-Aventis obesity drug, Acomplia (rimonabant) has approved to sell in Mexico. The first approval of the drug in North America. Acomplia Mexican approval has a diabetes indication, which is not included in the European label. Acomplia is a weight loss ...

Rimonabant Accepted for Filing By the FDA PARIS, June 23, 2005 -- Sanofi-aventis announced today that the United States Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) ...